20-deoxy-23-deoxy-20-(N-methyl-N-[1-(3-quinolyl)-1H-1,2,3-triazol-4-yl]lmethylamino)-23-(N,N-Dimethyl)amino-5-O-mycaminosyltylonolide

ID: ALA5189248

Chembl Id: CHEMBL5189248

PubChem CID: 86291474

Max Phase: Preclinical

Molecular Formula: C46H69N7O8

Molecular Weight: 848.10

Names and Identifiers

Canonical SMILES:  CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]2O)[C@@H](CCN(C)Cc2cn(-c3cnc4ccccc4c3)nn2)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CN(C)C

Standard InChI:  InChI=1S/C46H69N7O8/c1-11-40-34(25-50(6)7)20-28(2)16-17-38(54)29(3)21-33(18-19-52(10)26-35-27-53(49-48-35)36-22-32-14-12-13-15-37(32)47-24-36)45(30(4)39(55)23-41(56)60-40)61-46-44(58)42(51(8)9)43(57)31(5)59-46/h12-17,20,22,24,27,29-31,33-34,39-40,42-46,55,57-58H,11,18-19,21,23,25-26H2,1-10H3/b17-16+,28-20+/t29-,30+,31-,33+,34-,39-,40-,42+,43-,44-,45-,46+/m1/s1

Standard InChI Key:  AZRUCCFTSHLJLH-LDMPPBJASA-N

Alternative Forms

1. Parent:

   

   ALA5189248

   (4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-15-[(dimethylamino)methyl]-16-ethyl-4-hydroxy-5,9,13-trimethyl-7-[2-[methyl-[(1-quinolin-3-yltriazol-4-yl)methyl]amino]ethyl]-1-oxacyclohexadeca-11,

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 848.10

Molecular Weight (Monoisotopic): 847.5208

AlogP: 4.03

#Rotatable Bonds: 12

Polar Surface Area: 175.84

Molecular Species: BASE

HBA: 15

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 15

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.68

CX Basic pKa: 8.95

CX LogP: 4.42

CX LogD: 2.17

Aromatic Rings: 3

Heavy Atoms: 61

QED Weighted: 0.22

Np Likeness Score: 0.50

References

1. Zhai H, Luo C, Yang P, Zhang S, Wang H, Cao Y, Yang Y, Liu H, Kong X, Arhema Frejat FO, Ren C, Shi X, Wu C..  (2022)  Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.,  238  [PMID:35675753] [10.1016/j.ejmech.2022.114495]

Source

Source(1):

• Scientific Literature